دورية أكاديمية
Factors associated with ocular adverse event after immune checkpoint inhibitor treatment
| العنوان: | Factors associated with ocular adverse event after immune checkpoint inhibitor treatment |
|---|---|
| المساهمون: | Yong Joon Kim, Jihei Sara Lee, Junwon Lee, Sung Chul Lee, Tae-Im Kim, Suk Ho Byeon, Christopher Seungkyu Lee, Kim, Yong Joon |
| بيانات النشر: | Springer Verlag |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Adult, Aged, 80 and over, Antineoplastic Agents, Immunological / adverse effects, Antineoplastic Combined Chemotherapy Protocols / adverse effects, B7-H1 Antigen / antagonists & inhibitors, B7-H1 Antigen / immunology, CTLA-4 Antigen / antagonists & inhibitors, CTLA-4 Antigen / immunology, Drug Substitution / adverse effects, Eye Diseases / chemically induced, Eye Diseases / epidemiology, Eye Diseases / immunology, Female, Humans, Male, Middle Aged, Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors, Neoplasms / drug therapy, Neoplasms / immunology, Programmed Cell Death 1 Receptor / antagonists & inhibitors, Programmed Cell Death 1 Receptor / immunology, Protein Kinase Inhibitors / adverse effects, Proto-Oncogene Proteins B-raf / antagonists & inhibitors, Retrospective Studies, Risk Factors, Immune checkpoint inhibitor, Intraocular inflammation, Ocular adverse event |
| الوصف: | Ocular adverse events (OAEs) including vision-threatening intraocular inflammation after immune checkpoint inhibitor (ICI) treatment have been increasingly reported; however, the risk factors associated with OAEs remain elusive. Here, we determined the factors associated with OAEs after ICI treatment. We analyzed 40 consecutive patients who experienced OAEs after ICI treatments. The OAEs included anterior uveitis, chorioretinitis, papillitis, foveal interdigitation zone thickening/serous retinal detachment (IZT/SRD), retinal vascular occlusion, and strabismus and ptosis. Of 40 patients, 18 (45%) were treated with atezolizumab, 13 (33%) with pembrolizumab, 7 (18%) with nivolumab, 1 (3%) with ipilimumab/nivolumab, and the other 1 (3%) with durvalumab/tremelimumab. BRAF/MEK inhibitors were concurrently used in 19 (48%) patients. Occurrence of intraocular inflammation was significantly associated with previous ocular surgery and trauma history (P = 0.015) and pembrolizumab use (P = 0.031). Neuro-ophthalmic complications and IZT/SRD were associated with brain metastasis (P = 0.005) and treatment with BRAF/MEK inhibitor (P < 0.001), respectively. In extensive literature review for clinical cases, we identified seven cases with intraocular inflammation, which were not observed with ipilimumab treatment, that occurred after a change of the drug to pembrolizumab. Collectively, these findings provide better understandings of OAEs after ICI treatment. ; restriction |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 0340-7004 1432-0851 |
| العلاقة: | CANCER IMMUNOLOGY IMMUNOTHERAPY; J00445; OAK-2021-02466; https://ir.ymlib.yonsei.ac.kr/handle/22282913/183839Test; https://link.springer.com/article/10.1007%2Fs00262-020-02635-3Test; T202007144; CANCER IMMUNOLOGY IMMUNOTHERAPY, Vol.69 : 2441-2452, 2020-12 |
| DOI: | 10.1007/s00262-020-02635-3 |
| الإتاحة: | https://doi.org/10.1007/s00262-020-02635-3Test https://ir.ymlib.yonsei.ac.kr/handle/22282913/183839Test |
| حقوق: | CC BY-NC-ND 2.0 KR |
| رقم الانضمام: | edsbas.86B273D8 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 03407004 14320851 |
|---|---|
| DOI: | 10.1007/s00262-020-02635-3 |